UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

       DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): FEBRUARY 11, 2005

                             GLOBAL PHARMATECH, INC.
             (Exact name of registrant as specified in its charter)


           Delaware                      005-78248                33-0976805
----------------------------     ------------------------    -------------------
(State or other jurisdiction     (Commission File Number)      (IRS Employer
     of incorporation)                                       Identification No.)


          89 Ravine Edge Drive, Richmond Hill, Ontario, Canada L4E 4J6
              (Address of principal executive offices and Zip Code)

       Registrant's telephone number, including area code: (905) 787-8225

                                   Copies to:
                               Marc J. Ross, Esq.
                       Sichenzia Ross Friedman Ference LLP
                           1065 Avenue of the Americas
                            New York, New York 10018
                              Phone: (212) 930-9700
                               Fax: (212) 930-9725

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))
<PAGE>

ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.

      On February 11, 2005,  the Board of Directors of Global  Pharmatech,  Inc.
("the Company")  unanimously approved the dismissal of Russell Brennan ("Russell
Brennan") as its certifying  accountant and notified Russell Brennan that it was
terminating  Russell Brennan's  services.  The Company dismissed Russell Brennan
after the  Company  was  advised  by the staff of the  Securities  and  Exchange
Commission  on  December  26,  2004 that  Russell  Brennan  had not  applied for
registration  with  the  Public  Company  Accounting  Oversight  Board.  Also on
February 11, 2005, the Company  engaged its former  accountant,  Aaron Stein CPA
("Aaron  Stein") to serve as its  independent  registered  public  accountant to
review  the  Company's  financial  statements  for the  periods  ended  June 30,
September 30 and December 31, 2004.

      During the period from September 28, 2004 through February 11, 2005, which
is the period that Russell  Brennan was retained by the Company,  (i) there were
no  disagreements  between  the  Company  and  Russell  Brennan on any matter of
accounting  principles or practices,  financial statement disclosure or auditing
scope or procedure which, if not resolved to the satisfaction of Russell Brennan
would have caused Russell Brennan to make reference to the matter in its reports
on the Company's financial statements, and (ii) Russell Brennan's reports on the
Company's financial  statements did not contain an adverse opinion or disclaimer
of  opinion,  or was  modified  as to  uncertainty,  audit  scope or  accounting
principles. During the period from September 28, 2004 through February 11, 2005,
there were no reportable  events as the term described in Item  304(a)(1)(iv) of
Regulation S-B.

      During the two fiscal  years  ended  December  31, 2003 and 2002 and until
September  28,  2004,  Aaron  Stein  was  retained  as the  Company's  principal
accountant to audit and review the Company's  financial  statements  during such
periods.  During the two  fiscal  years  ended  December  31,  2003 and 2002 and
through February 12, 2005 the Company did not consult with Aaron Stein regarding
any matter that was either subject of  disagreement or event, as defined in Item
304(a)(1)(iv)(A)  of Regulation  S-B and the related  instruction to Item 304 of
Regulation  S-B,  or a  reportable  event,  as that  term is  explained  in Item
304(a)(1)(iv)(A) of Regulation S-B.

      On February 24, 2005, the Company  provided Russell Brennan with a copy of
the  disclosures it is making in response to Item 4.01 on this Form 8-K, and has
requested  that  Russell  Brennan  furnish  it with a  letter  addressed  to the
Securities  and  Exchange  Commission  stating  whether it agrees with the above
statements  within 10 business  days of the filing of this Form 8-K. Such letter
is filed herewith as Exhibit 16.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(A)   FINANCIAL STATEMENTS OF BUSINESS ACQUIRED.

      Not applicable.

(B)   PRO FORMA FINANCIAL INFORMATION.

      Not applicable.

(C)   EXHIBITS.


EXHIBIT NUMBER    DESCRIPTION
--------------    --------------------------------------------------------------
16.1              Letter from Russell Brennan dated February 11, 2005


                                       2
<PAGE>

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                           GLOBAL PHARMATECH, INC.


Date: February 24, 2005                    /s/ Xiaobo Sun
                                           -------------------------------------
                                           Xiaobo Sun
                                           President and Chief Executive Officer


                                       3
{"company-data": {"conformed-name": "Global Pharmatech, Inc.", "cik": "0001157300", "assigned-sic": "3714", "irs-number": "330976805", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-67884", "film-number": "05643874"}, "business-address": {"street1": "89 RAVINE EDGE DRIVE", "street2": "RICHMOND HILL", "city": "ONTARIO", "state": "A6", "zip": "L4E 4J6", "phone": "2129309700"}, "mail-address": {"street1": "89 RAVINE EDGE DRIVE", "street2": "RICHMOND HILL", "city": "ONTARIO", "state": "A6", "zip": "L4E 4J6"}, "former-company": [{"former-conformed-name": "AUTOCARBON INC", "date-changed": "20021118"}, {"former-conformed-name": "AUTOCARBON COM INC", "date-changed": "20020501"}, {"former-conformed-name": "AUTO CARBON COM INC", "date-changed": "20010810"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

       DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): FEBRUARY 11, 2005

                             GLOBAL PHARMATECH, INC.
             (Exact name of registrant as specified in its charter)

           Delaware                      005-78248                33-0976805
----------------------------     ------------------------    -------------------
(State or other jurisdiction     (Commission File Number)      (IRS Employer
     of incorporation)                                       Identification No.)

          89 Ravine Edge Drive, Richmond Hill, Ontario, Canada L4E 4J6
              (Address of principal executive offices and Zip Code)

       Registrant's telephone number, including area code: (905) 787-8225

                                   Copies to:
                               Marc J. Ross, Esq.
                       Sichenzia Ross Friedman Ference LLP
                           1065 Avenue of the Americas
                            New York, New York 10018
                              Phone: (212) 930-9700
                               Fax: (212) 930-9725

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))
ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.

      On February 11, 2005,  the Board of Directors of Global  Pharmatech,  Inc.
("the Company")  unanimously approved the dismissal of Russell Brennan ("Russell
Brennan") as its certifying  accountant and notified Russell Brennan that it was
terminating  Russell Brennan's  services.  The Company dismissed Russell Brennan
after the  Company  was  advised  by the staff of the  Securities  and  Exchange
Commission  on  December  26,  2004 that  Russell  Brennan  had not  applied for
registration  with  the  Public  Company  Accounting  Oversight  Board.  Also on
February 11, 2005, the Company  engaged its former  accountant,  Aaron Stein CPA
("Aaron  Stein") to serve as its  independent  registered  public  accountant to
review  the  Company's  financial  statements  for the  periods  ended  June 30,
September 30 and December 31, 2004.

      During the period from September 28, 2004 through February 11, 2005, which
is the period that Russell  Brennan was retained by the Company,  (i) there were
no  disagreements  between  the  Company  and  Russell  Brennan on any matter of
accounting  principles or practices,  financial statement disclosure or auditing
scope or procedure which, if not resolved to the satisfaction of Russell Brennan
would have caused Russell Brennan to make reference to the matter in its reports
on the Company's financial statements, and (ii) Russell Brennan's reports on the
Company's financial  statements did not contain an adverse opinion or disclaimer
of  opinion,  or was  modified  as to  uncertainty,  audit  scope or  accounting
principles. During the period from September 28, 2004 through February 11, 2005,
there were no reportable  events as the term described in Item  304(a)(1)(iv) of
Regulation S-B.

      During the two fiscal  years  ended  December  31, 2003 and 2002 and until
September  28,  2004,  Aaron  Stein  was  retained  as the  Company's  principal
accountant to audit and review the Company's  financial  statements  during such
periods.  During the two  fiscal  years  ended  December  31,  2003 and 2002 and
through February 12, 2005 the Company did not consult with Aaron Stein regarding
any matter that was either subject of  disagreement or event, as defined in Item
304(a)(1)(iv)(A)  of Regulation  S-B and the related  instruction to Item 304 of
Regulation  S-B,  or a  reportable  event,  as that  term is  explained  in Item
304(a)(1)(iv)(A) of Regulation S-B.

      On February 24, 2005, the Company  provided Russell Brennan with a copy of
the  disclosures it is making in response to Item 4.01 on this Form 8-K, and has
requested  that  Russell  Brennan  furnish  it with a  letter  addressed  to the
Securities  and  Exchange  Commission  stating  whether it agrees with the above
statements  within 10 business  days of the filing of this Form 8-K. Such letter
is filed herewith as Exhibit 16.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(A)   FINANCIAL STATEMENTS OF BUSINESS ACQUIRED.

      Not applicable.

(B)   PRO FORMA FINANCIAL INFORMATION.

      Not applicable.

(C)   EXHIBITS.

EXHIBIT NUMBER    DESCRIPTION
--------------    --------------------------------------------------------------
16.1              Letter from Russell Brennan dated February 11, 2005

                                       2
SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                           GLOBAL PHARMATECH, INC.

Date: February 24, 2005                    /s/ Xiaobo Sun
                                           -------------------------------------
                                           Xiaobo Sun
                                           President and Chief Executive Officer

                                       3